A strategic leader who brings deep knowledge and understanding of the pharmaceutical industry

Princeton, NJ, April 3, 2012- Laureate Biopharmaceutical Services, Inc. a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of James D. Utterback to the company’s Board of Directors.

“Jim is an invaluable addition to our board, and we are fortunate to have access to his deep industry knowledge,” said Michael A. Griffith, Chief Executive Officer. “Jim has more than 30 years of leadership experience building successful startups and public organizations in healthcare software, products and services globally. He has consistently innovated new approaches to growth and his customer-driven business philosophies complement Laureate’s quality-focused right-first-time model.”

Mr. Utterback most recently served as President, Chief Executive Officer and Board Member of M2Gen, part of the Moffitt Cancer Center in Tampa, Florida, and the third largest oncology academic medical research center in the U.S. He is Founder and Chairman of RxCeL Partners LLC, a healthcare consulting firm based in Philadelphia and Tampa. Mr. Utterback also held positions as Chief Executive Officer of SCIREX Corporation (now Premier Research), and President of the Pharmaceutical Division of Vivo Metrics, a global leader in ambulatory data collection. Earlier in his career, he was a Corporate Officer at Sanofi (then RPR) in Paris, France, and at Covance in Princeton, NJ. Mr. Utterback started his career at GE’s Medical Systems Division.  He earned a Master of Science in Industrial Psychology from Virginia Polytechnic Institute, and a Bachelor of Science in Psychology/Economics from Washington & Lee University.